Business Wire

PAYRETAILERS

3.2.2023 09:01:36 CET | Business Wire | Press release

Share
PayRetailers Appoints Lorenzo Pellegrino as New Chief Operating & Digital Officer

PayRetailers, LATAM’s leading all-in-one payment technology provider, has announced today the appointment of Lorenzo Pellegrino as Chief Operating & Digital Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230203005003/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lorenzo Pellegrino, Chief Operating & Digital Officer (Photo: PayRetailers)

Pellegrino comes to PayRetailers at a time of rapid growth, as it has expanded from seven to 11 offices, more than doubled headcount to over 200, and acquired Paygol in Chile and Pago Digital in Colombia. He will lead the deployment of PayRetailers’ resources, working to enhance the company’s technology offering and international platform – to support the merchant community, and the way it can access and move funds quickly and safely.

Payment industry leader

Pellegrino is a highly respected payments industry leader with almost 20 years of senior management experience. Most recently he was CEO of Skrill and NETELLER, heading their digital wallets businesses, alongside leading the marketing affiliate services company, Income Access – all part of the Paysafe Group Plc. While there, he coordinated efforts to drive Paysafe’s 2021 IPO on the New York Stock Exchange (NYSE).

Between 2012 and 2015, Pellegrino was also Executive Vice President for Digital Development for Optimal Payments Plc, leading their go-to-market strategy of the NETELLER wallet business and acquisition of Skrill. He spearheaded the company’s effort in integrating both wallet businesses which led to significant operational efficiencies and margin optimization. Before joining Optimal Payments, he held various executive level positions at Skrill (previously known as Moneybookers) and led their business development efforts in the US.

Lorenzo Pellegrino, COO & CDO, commented: “I’m thrilled to have joined a fast-growing business with so much potential. PayRetailers has a great business model and talented management team that will capitalize on the evolving payments landscape. Innovation and collaboration among our teams will lead us to great achievements and I am impressed by the team’s ability to deliver quality new products at speed.

“There are tremendous opportunities ahead and together we will seek to deliver greater value for our customers as we scale the business. Having been CEO in my previous role, I have a deep appreciation of what it takes to bring a business like PayRetailers to the next level of growth. I look forward to working with the board and leadership team as we usher in PayRetailers’ next chapter of growth and success, and I thank them for their warm welcome.”

Juan Pablo Jutgla, CEO & Founder of PayRetailers, commented: “In Lorenzo, we have chosen a leader uniquely positioned to execute and evolve PayRetailers’ strategy while continuing to generate growth. He has earned a reputation as a strong business leader with immense sector knowledge and has an excellent track record of leading businesses in both developed and emerging markets.

“We believe his strong leadership experience will help focus PayRetailers to become the payment method of choice to increase our community of merchants. We are delighted he will be supporting the company into a bright future and are excited as we enter the next chapter in PayRetailers’ journey.”

For more information about PayRetailers, please visit the company's website at https://payretailers.com.

About PayRetailers

Founded in 2017, PayRetailers is a leading global provider of online payment services with Latin DNA. Through one direct API, one technology platform and one contract, PayRetailers offer global merchants more than 250 payment methods without the need of a local entity.

PayRetailers platform provides businesses the ability to manage their payment ecosystem, analyze data, and simplify their customer experience through fully integrated solutions.

PayRetailers is headquartered in Spain with regional offices in Argentina, Brazil, Chile, Colombia, Mexico, Costa Rica, Paraguay and Peru.

Website: https://www.payretailers.com

LinkedIn: https://www.linkedin.com/company/pay-retailers/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005003/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye